Viehbacher surfaces at $2bn Bertarelli fund
This article was originally published in Scrip
Christopher Viehbacher, ex-CEO of Sanofi, has been appointed as the managing partner of Waypoint Capital's US-based fund, Gurnet Point Capital. Waypoint is the investment vehicle of the Bertarelli family, former owners of Serono, which was sold to Merck KGaA of Germany in 2007 in a deal worth around €10bn. Waypoint's chairman is Ernesto Bertarelli, the former CEO of Serono.
You may also be interested in...
Christopher Viehbacher, former Sanofi CEO and current managing partner at Gurnet Capital, will be charged with returning Biogen to growth with a second big Alzheimer’s launch looming.
Biotech stock indices have seen a recent recovery but remain well below their 2021 peaks raising questions about the likelihood of raising money for R&D. The number of companies announcing leadership changes, shifting pipeline priorities and job cuts is rising as a result.
Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.